-5%
This is indicated for the symptomatic relief of upper respiratory tract disorders accompanied by a non-productive cough which benefits from the administration of a nasal decongestant, a histamine H1 receptor antagonist, and an antitussive combination.
Indication
Flu, Colds, Runny nose, Dry coughs, Non-productive cough, Nasal congestion
Adult Dose
Oral Cough and common cold Adult: 2 teaspoonful three times a day.
Child Dose
Children Over 12 years 2 teaspoonful three times a day 6-12 years 1 teaspoonful three times a day 2-6 years 1/2 teaspoonful three times a day or as directed by the physician
Contraindication
Patients at risk of developing resp failure. During an acute attack. Patients receiving MAOI or for 2 wk after discontinuing them. Persistent or chronic cough.
Mode of Action
Triprolidine is a potent competitive histamine H1-receptor antagonist with mild sedating and antimuscarinic properties. Pseudoephedrine, an alpha- and beta-adrenergic receptor agonist, mediates vasoconstriction via direct stimulation of alpha-adrenergic receptors of the respiratory mucosa. Dextromethorphan is a centrally acting cough suppressant which acts on the cough centre in the medulla.
Precaution
3rd trimester of pregnancy; atopic childn; child <1 yr; sedated or debilitated patients; patients confined to supine position; history of asthma. Moderate to severe renal impairment; liver disease.
Side Effect
Dizziness, GI disturbances.
Interaction
Dextromethorphan: Tricyclic antidepressants (TCAs), antipsychotics, anxiolytics and hypnotics, cimetidine, ciprofloxacin, domperidone, metoclopramide, mexiletine, CYP2D6 inhibitors, ritonavir, alcohol. Potentially Fatal: Memantine, moclobemide. Triprolidine + Pseudoephedrine: Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine. Potentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.